{"id":"W2587420003","doi":"10.1093/annonc/mdw611","title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Chugai Pharmaceutical; Genentech; Ono Pharmaceutical; Astellas Pharma; Chinese University of Hong Kong; GlaxoSmithKline; AstraZeneca Korea; Clovis Oncology; Vertex Pharmaceuticals; International Association for the Study of Lung Cancer; Amgen; ACEA Biosciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Gefitinib; Afatinib; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Epidermal growth factor receptor; T790M; Proportional hazards model; Gastroenterology; Confidence interval; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002110978,0.0001980079,0.0005134832,0.00005275829,0.0002184923,0.00002845619,0.0004100123,0.0001094776,0.0001310517],"category_scores_gemma":[0.0002139502,0.0001374086,0.0000628543,0.00006975306,0.00014539,0.0002841666,0.0001367249,0.0001991474,0.000004529621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001519508,"about_ca_system_score_gemma":0.0009045755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004860412,"about_ca_topic_score_gemma":0.00325611,"domain_scores_codex":[0.9985179,0.0001036527,0.0003949507,0.000425882,0.0002565163,0.0003011113],"domain_scores_gemma":[0.99751,0.0005897768,0.000584762,0.0008863868,0.0003264374,0.0001026627],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4374608,0.01234429,0.3731115,0.0001566773,0.004163429,0.0003828336,0.009790896,0.0003911106,0.0002532324,0.0002016497,0.0150372,0.1467064],"study_design_scores_gemma":[0.5263442,0.01104405,0.4545453,0.000318082,0.001319141,9.300358e-7,0.0006896824,0.0009254987,0.0006052862,0.00003582943,0.003885781,0.0002862249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853675,0.0003797855,0.00004137723,0.003095615,0.0009961897,0.001850919,0.001815455,0.00001193774,0.006441195],"genre_scores_gemma":[0.9958762,0.0002306448,0.0004865179,0.0005101748,0.0003018615,0.000166329,0.002230125,0.00002617568,0.0001719901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1464202,"threshold_uncertainty_score":0.7347522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08223081129384406,"score_gpt":0.4570319687057121,"score_spread":0.374801157411868,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}